Jim Pearce

Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.

Analyst Articles

TRADE ALERTTRADE INSTRUCTIONSDate: September 7, 2016Name: Cal-Maine FoodsSymbol: CALMType: OpenLimit: Buy below $45TRADE TARGETSHolding Period: 183 daysAverage Return: 11.1%Annualized Return: 22.3%TRADE RATIONALECal-Maine Foods is the largest egg producers and marketer in the U.S. It sells its eggs to grocery store chains and food distributors including major brands such as Egg-Lands… Read More

Shares of cancer immunotherapy company Juno Therapeutics (JUNO) fell nearly 10% last Wednesday after rival drug manufacturer Novartis announced it is reorganizing its operations by consolidating its cell and gene therapy unit so that it is no longer a separate division. Although Novartis issued a press release reaffirming its commitment… Read More

For a company built around the idea of democratizing the cost of travel, The Priceline Group (PCLN) doesn’t like democracy too much when it comes to shareholders. And it also doesn’t want to pay dividends. Not only does it sport the second highest share price of all companies in the… Read More

Earlier this month I recommended buying a put option on Autodesk (NSDQ: ADSK) on the belief that it was fully valued and ripe for a fall heading into last week’s earnings announcement. At the time of that article (August 18th) ADSK stock was priced at $63, which equated to… Read More

At some point not enough bogeymen exist to justify keeping the U.S. economy from operating under normal conditions.But on the heels of July’s surprisingly strong employment report, Fed chair Janet Yellen may feel compelled to raise interest rates next month if the rest of the economy remains on track. Inflation is also… Read More

On August 10th Argos Therapeutics (NasdaqGM: ARGS) released its second quarter earnings report, which in terms of financial performance was about what everyone expected. Although earnings came in worse than expected at a loss of 48 cents versus the analysts’ estimate of minus 40 cents, it beat on its… Read More

It was the best of Apples, it was the worst of Apples—depending on what type of investor you are. At the same time a high-profile hedge fund manager was reducing his position in Apple during the second quarter of this year, legendary investor Warren Buffett was increasing his stake by 55%. Read More